HLA-B38 Antigen

A specific HLA-B surface antigen subtype. Members of this subtype contain alpha chains that are encoded by the HLA-B*38 allele family.

Also Known As:

HLA B38; HLA Class I Histocompatibility Antigen, B-38 alpha Chain; HLA-B38; Antigen, HLA B38; Antigen, HLA-B38; B38 Antigen, HLA; HLA Class I Histocompatibility Antigen, B 38 alpha Chain; HLA B38 Antigen

Networked: 19 relevant articles (0 outcomes, 3 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Anholts, J D H: 1 article (08/2017)
2.	Claas, F H J: 1 article (08/2017)
3.	Franke-van Dijk, M E I: 1 article (08/2017)
4.	Heutinck, K M: 1 article (08/2017)
5.	Roelen, D L: 1 article (08/2017)
6.	Ten Berge, R J M: 1 article (08/2017)
7.	Yong, S L: 1 article (08/2017)
8.	Zhang, X Q: 1 article (08/2017)
9.	van Miert, P P M C: 1 article (08/2017)
10.	van den Heuvel, H: 1 article (08/2017)

Related Diseases

1.	Pemphigus (Pemphigus Vulgaris) 09/15/1997 - "Previous studies showed that almost all Ashkenazi Jewish patients with pemphigus vulgaris carried the extended haplotype [HLA-B38, SC21, DRB10402, DQB10302] or [HLA-B35, SC31, DRB10402, DQB10302] or class II fragments of them. " 04/01/2004 - "Studies showed that the associated HLA haplotype in Jewish pemphigus vulgaris (PV) patients is HLA-B38, DRB10402, and DQB10302; or HLA-B35, DRB10402, and DQB10302. " 06/01/1991 - "Previous studies demonstrated that HLA-DR4 was markedly increased among Ashkenazi Jewish patients with pemphigus vulgaris (PV), almost entirely as the common Jewish extended haplotype [HLA-B38, SC21, DR4, DQw8] or as the haplotype HLA-B35, SC31, DR4, DQw8, and that HLA-DR4, DQw8 was distributed among patients in a manner consistent with dominant expression of a class II (D-region or D-region-linked) susceptibility gene. "
2.	Agranulocytosis (Granulocytopenia) 02/01/1998 - "= 1, P = 0.11), although the agranulocytosis patients had a higher frequency of the HLA B38 antigen (8/11 or 72% vs. 6/50 or 12%; chi 2 = 18.7, d.f. " 10/01/1990 - "The incidence of HLA-B38, DR4, DQw3 was significantly increased in patients with agranulocytosis (five of five patients) compared with control patients of Ashkenazi Jewish ancestry (two of 17 patients). " 02/01/1998 - "HLA-B38 and clozapine-induced agranulocytosis in Israeli Jewish schizophrenic patients." 04/01/1992 - "HLA-B38 and clozapine-induced agranulocytosis." 01/01/1992 - "An association between the HLA-B38, -DR4, -DQw3 haplotype and clozapine-induced agranulocytosis was found in all Jewish cases (7/7; 100%); in contrast only 4 of 21 (19%) Jewish control (nonagranulocytic) patients carried this haplotype. "
3.	Psoriatic Arthritis 12/17/2006 - "There was a higher frequency of HLA-B38 in psoriatic arthritis patients with erythroderma." 01/01/1987 - "The frequency distribution of HLA-B38 and HLA-B39 was studied in a group of 50 unrelated psoriatic arthritis patients. "
4.	T-Cell Leukemia (Leukemia, T Cell) 08/01/1994 - "The only HLA class I structure expressed by this T-cell leukemia which is consistent with the binding of peptides carrying this sequence motif is HLA-B38. " 08/01/1994 - "HLA class I self peptides isolated from a T-cell leukemia reveal the allele-specific motif of HLA-B38."
5.	Viremia 02/01/2013 - "On logistic regression analysis, presence of the HLA-A01 allele was associated with SVR (OR: 0.50; 95% CI: 0.28-0.89; P = 0.02) and HLA-B38 can predict non response to therapy (OR: 7.92; 95% CI: 1.67-37.54; P = 0.009) with an overall accuracy of 60%.Severe fibrosis (OR: 3.035; 95% CI: 1.521-6.091; P = 0.002), high viremia (OR: 2.69; 95% CI: 1.11-6.53; P = 0.005) and steatosis (OR: 2.1; 95% CI: 1.002-3.90; P = 0.041) predicted no response with an overall accuracy of 81.8%. HLA-A01 and HLA-B38 alleles are associated with and may have a role in the outcome of response to Peg-IFN plus ribavirin therapy in Egyptian patients diagnosed with chronic HCV infection. "

Related Drugs and Biologics

1.	HLA-B35 Antigen (HLA B35 Antigen)
2.	HLA-DR4 Antigen (HLA DR4 Antigen)
3.	Clozapine (Clozaril)
4.	HLA-A Antigens (HLA-A)
5.	HLA-B51 Antigen
6.	HLA-B39 Antigen
7.	HLA-B13 Antigen
8.	HLA-DR2 Antigen (HLA DR2 Antigen)
9.	HLA-B27 Antigen (HLA B27 Antigen)
10.	HLA-A2 Antigen (HLA A2 Antigen)

Related Therapies and Procedures

1.	Therapeutics